Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Vistagen Therapeutics Inc

VTGN ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: HOLD

Last Close

$0.24

▲ +1.20%

Market Cap $10.83M · Vol 259.57K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$10.83M

Micro Cap

Div Yield

N/A

EPS Growth

+19.40%

YoY

RSI (14)

49.67

Momentum

Beta

0.38

vs Market

52W High

$5.13

95.24% below

52W Low

$0.20

22.92% above

Volume

259.57K

Avg 401.04K

P/B

0.64

Price-to-book

ROE

N/A

Return on equity

Free Float

99.63%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Vistagen Therapeutics Inc (VTGN) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does VTGN pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-8.82%

+3.83%

-61.70%

-56.36%

YTD

-63.14%

-92.03%

-95.76%

-99.70%

Financials & Valuation

TTM · Annual

Total Revenue	$1.27M
Net Income	$-69,685,000.00
Revenue Growth (YoY)	+504.92%
Gross Margin	100.00%
Operating Margin	-5,683.69%
Net Profit Margin	-5,491.33%
ROE	N/A
ROA · ROIC	-104.85% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	17.15
P/B	0.64
P/FCF	N/A
EPS Growth	+19.40%
Outstanding Shares	44.38M

Technical Indicators

50-Day SMA	$0.35
200-Day SMA	$1.10
RSI (14)	49.67
Beta	0.38
52-Week High	$5.13
52-Week Low	$0.20

Volume Today	259.57K
Avg Daily Volume (30D)	401.04K
Relative Volume	0.65x
Volatility (10D)	56.54
Volatility (30D)	75.12
Free Float	99.63%

Analyst Consensus

HOLD

Current Price $0.24

Mean Target $0.97

52W Low$0.20 52W High$5.13

Current

Target

$0.20 $5.13

Current Analyst target

+296.18% upside potential · 5 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001S67BH3

ISINUS92840H4002

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 10, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -0.39% ARGX.BR argenx SE +1.90% ARGX argenx SE +0.16% INSM Insmed Inc +0.55% 2269.HK WuXi Biologics (Cayman) Inc +2.74%

Company Profile

Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. Its neuroscience product candidates include Fasedienol, Itruvone, PH15, PH80, and PH284. Fasedienol, its lead clinical-stage product candidate, is a synthetic neuroactive intranasal pherine in an ongoing U.S. registration-directed Phase III clinical development program for the acute treatment of anxiety in adults with SAD. Its neuroscience pipeline also includes an oral prodrug with potential to treat certain neurological conditions involving the NMDA receptor.